Estrogen Receptor β in Prostate Cancer

To the Editor: In the Prostate Cancer Prevention Trial,1 more than 18,000 healthy volunteers were randomly assigned to receive either finasteride (5 mg daily) or placebo. The incidence of prostate cancer in the finasteride group was 18.4 percent, as compared with 24.4 percent in the placebo group. A bigger surprise was that the incidence of tumors with a Gleason grade of 7, 8, 9, or 10 was higher in the finasteride group than in the placebo...